.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Mallinckrodt
Novartis
Baxter
Fuji
AstraZeneca
Dow
Colorcon
Cipla
Deloitte

Generated: December 16, 2017

DrugPatentWatch Database Preview

Valeant Pharm Intl Company Profile

« Back to Dashboard

What is the competitive landscape for VALEANT PHARM INTL, and what generic alternatives to VALEANT PHARM INTL drugs are available?

VALEANT PHARM INTL has forty-four approved drugs.

There is one US patent protecting VALEANT PHARM INTL drugs.

There are one hundred and one patent family members on VALEANT PHARM INTL drugs in twenty-six countries and seven supplementary protection certificates in five countries.

Summary for Valeant Pharm Intl

International Patents:101
US Patents:1
Tradenames:37
Ingredients:32
NDAs:44
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharm IntlDIPHENHYDRAMINE HYDROCHLORIDEdiphenhydramine hydrochlorideCAPSULE;ORAL080596-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharm IntlDIPHENHYDRAMINE HYDROCHLORIDEdiphenhydramine hydrochlorideCAPSULE;ORAL080592-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharm IntlDALMANEflurazepam hydrochlorideCAPSULE;ORAL016721-002Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Valeant Pharm IntlRAUWOLFIA SERPENTINArauwolfia serpentina rootTABLET;ORAL009668-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharm IntlDALMANEflurazepam hydrochlorideCAPSULE;ORAL016721-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharm IntlDIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATEatropine sulfate; diphenoxylate hydrochlorideTABLET;ORAL087195-001Feb 16, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharm IntlLIBRIUMchlordiazepoxide hydrochlorideCAPSULE;ORAL085461-001Approved Prior to Jan 1, 1982ABRXNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharm IntlBENDOPAlevodopaCAPSULE;ORAL016948-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharm IntlLEVO-DROMORANlevorphanol tartrateINJECTABLE;INJECTION008719-001Dec 19, 1991DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharm IntlTRISORALENtrioxsalenTABLET;ORAL012697-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Valeant Pharm Intl

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharm IntlPERMAXpergolide mesylateTABLET;ORAL019385-002Dec 30, 1988► Subscribe► Subscribe
Valeant Pharm IntlPERMAXpergolide mesylateTABLET;ORAL019385-002Dec 30, 1988► Subscribe► Subscribe
Valeant Pharm IntlVIRAZOLEribavirinFOR SOLUTION;INHALATION018859-001Dec 31, 1985► Subscribe► Subscribe
Valeant Pharm IntlPERMAXpergolide mesylateTABLET;ORAL019385-003Dec 30, 1988► Subscribe► Subscribe
Valeant Pharm IntlPERMAXpergolide mesylateTABLET;ORAL019385-001Dec 30, 1988► Subscribe► Subscribe
Valeant Pharm IntlPERMAXpergolide mesylateTABLET;ORAL019385-001Dec 30, 1988► Subscribe► Subscribe
Valeant Pharm IntlLIBRELEASEchlordiazepoxideCAPSULE, EXTENDED RELEASE;ORAL017813-001Sep 12, 1983► Subscribe► Subscribe
Valeant Pharm IntlPERMAXpergolide mesylateTABLET;ORAL019385-003Dec 30, 1988► Subscribe► Subscribe
Valeant Pharm IntlVIRAZOLEribavirinFOR SOLUTION;INHALATION018859-001Dec 31, 1985► Subscribe► Subscribe
Valeant Pharm IntlPERMAXpergolide mesylateTABLET;ORAL019385-002Dec 30, 1988► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for VALEANT PHARM INTL drugs

Drugname Dosage Strength Tradename Submissiondate
ribavirinFor Inhalation Solution6 gm/vialVIRAZOLE5/22/2014

Non-Orange Book Patents for Valeant Pharm Intl

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,767,097 Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes► Subscribe
6,509,320 Purine L-nucleosides, analogs and uses thereof► Subscribe
6,455,690 L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine► Subscribe
6,479,463 Purine L-nucleosides, analogs and uses thereof► Subscribe
6,423,695 Cytokine related treatments of disease► Subscribe
6,063,772 Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Valeant Pharm Intl Drugs

Country Document Number Estimated Expiration
Australia727177► Subscribe
Poland187439► Subscribe
Australia736075► Subscribe
Australia700642► Subscribe
Spain2172764► Subscribe
Australia6023898► Subscribe
Brazil9707154► Subscribe
Australia4899997► Subscribe
Israel125088► Subscribe
Norway20004327► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Valeant Pharm Intl Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 00042Denmark► SubscribePRODUCT NAME: KOMBINATION AF SAFINAMID, HERUNDER SAFINAMID METHANSULFONAT, OG LEVODOPA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150226
782Luxembourg► SubscribePRODUCT NAME: SAFINAMIDE A UTILISER EN COMBINAISON AVEC LEVODOPA/PDI, ET EVENTUELLEMENT AVEC D'AUTRES MEDICAMENTS PD , POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON; FIRST REGISTRATION DATE: 20150224
13/055Ireland► SubscribePRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624
C/GB10/012United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
323Luxembourg► SubscribePRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624
C0038France► SubscribePRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
C0062France► SubscribePRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Queensland Health
Cerilliant
Novartis
Deloitte
McKesson
Federal Trade Commission
Citi
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot